Sanofi and Genzyme recover domain at WIPO
16-11-2016
Sanofi and Boehringer Ingelheim to swap businesses
28-07-2016
nitpicker / Shutterstock.com
Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sanofi, Kymab, immunotherapy, Principia Biopharma, Kiadis, KY1005
